FDA, academia and industry team up to end hepatitis C
A research consortium known as the Hepatitis C Therapeutic Registry
and Research Network, or HCV-TARGET, has joined forces with the FDA to
share national data on how newly approved therapies for hepatitis C are
used and managed in routine practice. HCV-TARGET is led jointly by
investigators at the University of Florida and the University of North Carolina at Chapel Hill and is sponsored in part by multiple pharmaceutical companies.
The new partnership’s goal is to establish research collaborations
using the HCV-TARGET database to better inform patients and clinicians
about hepatitis C therapies.